{"id":3069,"date":"2026-10-31T09:33:07","date_gmt":"2026-10-31T09:33:07","guid":{"rendered":"https:\/\/newsraise.com\/in\/2026\/10\/31\/india-halts-sun-pharma-eye-medicine-production\/"},"modified":"2026-10-31T09:33:07","modified_gmt":"2026-10-31T09:33:07","slug":"india-halts-sun-pharma-eye-medicine-production","status":"publish","type":"post","link":"https:\/\/newsraise.com\/in\/2026\/10\/31\/india-halts-sun-pharma-eye-medicine-production\/","title":{"rendered":"India halts Sun Pharma&#8217;s eye\u2011medicine production after quality lapses"},"content":{"rendered":"\n<!-- Quick Adsense WordPress Plugin: http:\/\/quickadsense.com\/ -->\n<div class=\"9fece8afa224fd09e54b043d0febfb58\" data-index=\"1\" style=\"float: none; margin:10px 0 10px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- NR ATF -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-8898941184964366\"\r\n     data-ad-slot=\"4839033563\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p>India\u2019s top drug\u2011regulating bodies have ordered Sun Pharmaceutical Industries Ltd. to cease manufacturing, selling and distributing ophthalmic medicines at its Assam facility until a satisfactory compliance report is filed. The decision follows a joint inspection by the Central Drugs Standard Control Organisation (CDSCO) and the Drugs Controller Office of Assam that identified serious gaps in the plant\u2019s quality\u2011management system.<\/p>\n<h2>Regulators impose shutdown after joint inspection<\/h2>\n<p>The shutdown order was issued on August\u202f20, after inspectors from the federal and state agencies conducted a combined review of the Kokjhar\u2011village plant in Assam\u2019s Kokjhar village. The agencies cited failures in the system designed to ensure product quality and safety. Earlier, on August\u202f10, the regulators had issued a show\u2011cause notice demanding explanations for the identified deficiencies.<\/p>\n<p>Sun Pharma had already begun a voluntary recall in July, withdrawing roughly 11 eye\u2011care brands as a precautionary measure. The recall covered 332 batches of ophthalmic suspension products \u2013 sterile liquids used to treat a range of eye conditions. The company\u2019s internal notice to its stockists described the withdrawal as a \u201cprecautionary measure,\u201d but did not confirm whether the recalled batches were contaminated.<\/p>\n<h2>Recall scope and safety concerns<\/h2>\n<p>Among the products listed in the recall were Lotepred 1\u202fpercent 5\u202fml eye drops, Nepalact OD eye drops, Nepalact\u2011Z, Brinzotim eye drops 5\u202fml and Depopred 2\u202fml. These formulations are typically prescribed for eye inflammation, infections and chronic ocular diseases. The recall notice did not specify whether the products were exported from India, nor were any adverse patient reports publicly disclosed.<\/p>\n<p>Based on packaging information, Reuters determined that most of the recalled items originated from the Assam plant. Industry experts, speaking on condition of anonymity, estimated that the 332 batches could translate into hundreds of thousands of individual eye\u2011drop bottles, underscoring the potential scale of the issue.<\/p>\n<p>In June, the All India Ophthalmological Society (AIOS) issued a patient\u2011safety advisory after some batches of Predmet eye drops were found to be contaminated. Santosh Honavar, a doctor and secretary of AIOS, told Reuters that infections had been reported in patients using the affected drops and that sealed bottles had been investigated and confirmed contaminated. Sun Pharma also recalled the Predmet drops, though it did not comment on the AIOS advisory.<\/p>\n<h2>Impact on Sun Pharma and the wider industry<\/h2>\n<p>Sun Pharma, the largest pharmaceutical company in India, had positioned the Assam facility as a future hub for sterile product manufacturing \u2013 a segment the firm identifies as a key global growth driver. Ophthalmology accounts for about 3\u202fpercent of the company\u2019s domestic revenue, according to its 2025\u201126 annual report, and represents a strategic market for the United States.<\/p>\n<p>The regulator\u2019s order means the plant cannot resume ophthalmic production until a compliance report satisfactory to the authorities is submitted. Sun Pharma has already provided such a report, which is currently under review by the CDSCO, according to an official who requested anonymity because they are not authorized to speak to the media.<\/p>\n<p>The halt follows earlier regulatory scrutiny of Sun Pharma\u2019s sterile manufacturing sites. In 2023, the U.S. Food and Drug Administration suspended shipments from the company\u2019s Halol plant in Gujarat after inspectors raised concerns about contamination controls. The present action adds to a growing pattern of heightened oversight of Indian drug quality, driven in part by recent tragedies linked to locally produced cough syrups that caused child deaths in India, the Gambia and Uzbekistan.<\/p>\n<p>Financially, Sun Pharma reported a decline in second\u2011quarter profit on October\u202f30, a dip attributed to a one\u2011time charge related to its acquisition of the U.S. firm Organon. While the eye\u2011drop recall coincided with the profit dip, the company has not disclosed the direct financial impact of the recall or the shutdown.<\/p>\n<p>Regulators have not issued a public health alert related to the recall, and the Indian drug authority declined to comment on the matter. The agency\u2019s decision to stop production, however, signals a firm stance on compliance and patient safety, especially as the country\u2019s pharmaceutical sector faces increasing scrutiny both domestically and abroad.<\/p>\n<p>Sun Pharma\u2019s website maintains that the company adheres to a single global quality standard, but the ongoing investigations and the requirement for a compliance report highlight the challenges the firm faces in meeting the expectations of regulators and healthcare professionals alike.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>India&#8217;s drug regulator ordered Sun Pharma to stop making eye\u2011drops at its Assam plant after a joint inspection uncovered quality\u2011system failures and a recall of 332 batches.<\/p>\n","protected":false},"author":2,"featured_media":3070,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[299],"tags":[3445,3447,3446,3444,3443],"class_list":["post-3069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-drug-recall","tag-india-health-safety","tag-ophthalmic-products","tag-pharmaceutical-regulation","tag-sun-pharma","entry"],"_links":{"self":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts\/3069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/comments?post=3069"}],"version-history":[{"count":0,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts\/3069\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/media\/3070"}],"wp:attachment":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/media?parent=3069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/categories?post=3069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/tags?post=3069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}